Skip to Main Content
Contribute Try STAT+ Today

They’re known colloquially as “suicide headaches,” because the pain can be so severe that people who suffer from them take their own lives at a disproportionately high rate.

Cluster headaches, as the rare condition is known, are characterized by bursts of severe pain in cyclical patterns. They’re often misdiagnosed and undertreated. But on Tuesday, the Food and Drug Administration cleared a new, first-of-its kind option for such patients: a handheld device, designed to be used by patients to zap their own necks with a mild electrical signal to relieve symptoms.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Comments are closed.